GV — Genomic Vision SA Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.11 | 1.77 | 1.08 | 0.994 | 1.03 |
Cost of Revenue | |||||
Gross Profit | -2.63 | -1.78 | -1.18 | -1.22 | -1.69 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8.01 | 6.38 | 6.24 | 5.89 | 7.15 |
Operating Profit | -6.9 | -4.61 | -5.15 | -4.89 | -6.12 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.9 | -4.61 | -5.18 | -4.96 | -6.79 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.9 | -4.61 | -5.18 | -5 | -6.79 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.9 | -4.61 | -5.18 | -5 | -6.79 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.9 | -4.61 | -5.18 | -5 | -6.79 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.754 | -0.164 | -0.119 | -0.099 | -0.096 |
Dividends per Share |